Head-to-head · WeighScore
Alan Meds vs JRNYS
The verdict
Alan Meds takes it — 71.1/100 to 62.5/100.
Alan Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth platform offering compounded semaglutide and tirzepatide with multiple administration formats including microdosing and oral options.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Alan Meds | JRNYS |
|---|---|---|
| WeighScore | 71.1/100 | 62.5/100 |
| Grade | C | C |
| Scorecard rank | #98 | #267 |
| Semaglutide | $158/mo (compounded) | Not disclosed |
| Tirzepatide | $295/mo (compounded) | Not disclosed |
| Coverage | 46 states | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #98 · C
Strengths
- Aggressively low monthly pricing
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
- Multiple administration formats
Where it loses points
- Limited public information on program details
Graded #267 · C
Strengths
- Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
- The membership band is published before intake and is banded openly by level of coach support
- Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
- Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
- Members with commercial insurance may pay around $25 a month for the medication after any deductible
Where it loses points
- The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
- No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
- The best case depends on commercial insurance coverage; without it the medication cost is unknown
- No compounded option is disclosed — the programme is brand-focused, and brand list prices are the dearest route to a GLP-1
- The states it can prescribe in are not published
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.